hrp0094p1-6 | Adrenal A | ESPE2021

International practice of therapy monitoring in congenital adrenal hyperplasia – Real World data from the I-CAH registry

Lawrence Neil , Bacila Irina , Dawson Jeremy , Bryce Jillian , Akker Erica van den , Bachega Tania Aparecida Sartori Sanchez , Baronio Federico , Birkebaek Niels Holtum , Bonfig Walter , Claahsen Hedi , Costa Eduardo Correa , Devries Liat , Elsedfy Heba , Guven Ayla , Hannema Sabine , Iotova Violeta , Kamp Hetty J van der , Leon Maria Clemente , Lichiardopol Corina Raducanu , Milenkovic Tatjana , Neumann Uta , Nordenstrom Ana , Poyrazoglu Sukran , Probst-Scheidegger Ursina , Sanctis Luisa De , Thankamony Ajay , Vieites Ana , Yavas Zehra , Ahmed Faisal , Krone Nils ,

Aim: Recommendations for the management of Congenital Adrenal Hyperplasia (CAH) outline a target 17-OH Progesterone (17OHP) of 12-36nmol/l, but do not specify target concentrations for Androstenedione (D4). We aimed to study the temporal variations of these biomarkers in patients from different geographical regions.Method: This retrospective multi-centre study, including 21 centres (14 countries), analysed serum biomarke...

hrp0082p1-d3-196 | Pituitary | ESPE2014

Rathke Cleft Cysts and Endocrine Dysfunction in Children

Dupre Marie , Brioude Frederic , Berard Laurence , Esteva Blandine , Houang Muriel

Background: Rathke’s cleft cysts (RCC) are benign lesions of the pituitary gland, remnants of Rathke’s pouch. RCC have rarely been reported in children and adolescents and are usually known as asymptomatic but some cases may be associated with hormonal disturbances.Objective and hypotheses: The aim of the study was to assess the characteristics and frequency of endocrine disturbances in children with RCC.Method: We retros...

hrp0097p2-270 | Late Breaking | ESPE2023

The effect of dulaglutide (GLP-1agonist) and metformin combination on weight loss in obese patients with and without type 2 diabetes. Gold combination?

Zohrabyan Naira , Hakobyan Sonya

Background: GLP-1 agonists have a special place in the treatment of type 2 diabetes mellitus (T2DM). Dulaglutide is GLP-1agonist with important advantages, it doesn’t cause hypoglycemia, reduces weight and decreases HbA1c with sufficient level. GLP-1 agonists are also involved in the treatment of obesity.Objectives: The purpose of this study was to present the efficacy of Dulaglutide (GLP-1) in obesity with and wit...

hrp0086p2-p872 | Syndromes: Mechanisms and Management P2 | ESPE2016

Metamemory in Turner Syndrome: A Study Comparing Episodic and Semantic Memory

Souchay Celine , Gourisse Laurene , Brigitte Mignot , Magali Avila , Bertrand Anne-Marie , Faivre Laurence

Background: Tuner syndrome (TS) is associated with a distinctive cognitive profile including memory impairments. The current study focuses on metamemory defined as our knowledge about our memory functioning and yet never been explored in TS.Objective and hypotheses: The aim of this preliminary study is thus to determine what patients with TS know about their memory functioning and when their memory is impaired whether or not they are aware of those defic...

hrp0082p3-d3-655 | Autoimmune Endocrine Disease | ESPE2014

A Conservative Approach to the Management of Endocrine Neoplasia in Carney Complex in an Adolescent Male

Frerichs Carley , Didi Mohammed , Abernethy Laurence , Kenny Simon , Ellis Ian , Blair Joanne

Background: Carney complex (CC) is a rare, dominantly inherited condition due to mutations of the tumour suppressor gene PRKAR1A. Endocrine manifestations include: Cushing’s syndrome (CS) due to primary pigmented nodular adrenocortical disease, pituitary adenomas, testicular neoplasms, thyroid tumours, and ovarian cysts. The management of some of these tumours is controversial.Objective and hypotheses: To describe conservative management of CC.<...

hrp0082p3-d1-812 | Growth | ESPE2014

Maternal Inheritance of an Heterozygous Exon 4 IGF1 Gene Mutation (g.65941 G>A) in an IUGR Child with Mild Post Natal Growth Retardation

Houang Muriel , Brioude Frederic , Azzi Salah , Thibaud Nathalie , Perin Laurence , Le Bouc Yves , Netchine Irene

Background: We already described a partial IGF1 primary deficiency due to an exon 4 homozygous missense mutation (g.65941 G>A). A few patients are now described with a heterozygous IGF1 deletion or mutation, questioning about IGF1 haplo insufficiency role in short stature.Results: We describe a boy born from consanguineous parents, with an intra uterine growth restriction (IUGR). Birth weight: 2520 g (−1 SDS) birth length: 46 ...

hrp0084p3-1052 | Growth | ESPE2015

MEGHA: Observational Study on Prescription of the GH Saizen in Adults in France

Cortet Christine , Pugeat Michel , Fresneau Laurence , Sadoul Jean-Louis , Young Jacques , Souberbielle Jean-Claude , Chanson Philippe

Background: Final results from MEGHA study required by Health French Authorities (HAS).Objective and hypotheses: Objectives are to carry out longitudinal follow-up during maximum 5 years of AGHD patients treated with Saizen, with a description of prescription modalities, demographic and clinical characteristics, patient compliance, product safety, and quality of life.Method: MEGHA is a multicentric study, with prospective follow-up...

hrp0089rfc7.5 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2018

Alteration of Renal Corticosteroid Signaling Pathways in Preterm Infants: Neonatal Adaptation and Developmental Programming of Hypertension

Dumeige Laurence , Nehlich Melanie , Lhadj Christophe , Viengchareun Say , Xue Qiong-Yao , Pussard Eric , Lombes Marc , Martinerie Laetitia

Introduction: Prematurity, a worldwide health issue, is often associated with renal tubular immaturity leading to major salt loss, whose mechanisms remain poorly understood. Moreover, these premature infants are prone to develop hypertension early in adulthood.Objective: To study the ontogenesis of renal mineralocorticoid and glucocorticoid signaling pathways in preterm infants and to evaluate their respective role during neonatal adaptation and in the e...

hrp0086p2-p163 | Bone &amp; Mineral Metabolism P2 | ESPE2016

Bone Health Index is Low at Diagnosis of Growth Hormone Deficiency, and Improves During Growth Hormone Therapy

Blair Joanne , Povall Ann , McCoy Paul , Dharmaraj Poonam , Das Urmi , Ramakrishnan Renuka , Senniappan Senthil , Abernethy Laurence , Didi Mohammed

Background: BoneXpert software calculates bone health index (BHI) from cortical thickness and mineralisation of three metacarpals, and bone age (BA) using 13 bones: Radius, ulna and bones in ray 1, 3, 5. Strong correlations between BoneXpert BHI and dual-energy x-ray absorptiometry (DXA) and peripheral quantitative computed CT (pQCT) measurements are reported 1. Low bone mineral density (BMD), measured by DXA, and improvement with GH is described in childhood GH deficiency (GH...